FINALLY! An Ad Guaranteed Way to Make YOU $$$

Thursday, March 19, 2020

UPDATE Doctors find three common drugs might save coronavirus victims

Update for the story below.
china conducted a test of Kaletra, a combination of two antiviral medicines, lopinavir and ritonavir and found to be ineffective against COVID-19

The latest candidate drug to treat this coronavirus is Gilead's remdesivir which is being tested by the WHO and the NIH.

NO results yet for ritonavir.

The tests on lopinavir and ritonavir was conducted on 199 patients with 99given the experimental combo drug treatment and 100 receiving standard supportive care.

The mortality ratio after 28 days was similar for both groups showing the Kaletra combination was ineffective despite early reports out of Thailand where it was uses successfully. That doesn't mean the Bangkok doctors falsified either the treatment or the result, just that because they only had one patient there could have been other factors which lead to her quick recovery. Also, with viral diseases people often seem to go into a kind of remission only to have the disease return in a week or two. This is what leads people to think they aren't becomming immune from a vaccine or from catching a disease -they never fully recovered the first time. There is no report of a follow up on the Bangkok patient or her current condition.

New England Journal of Medicine Report on Trial
https://www.nejm.org/doi/full/10.1056/NEJMoa2001282

Doctors at the Rajavithi Hospital in Bangkok tested a mix of HIV and influenza medicines which saved the life of an elderly woman with a severe case of 2019nCoV from Wuhan China.

The treatment used  lopinavir and ritonavir along with high dosage oseltamivir, a common flu treatment.

The flu medicine was formerly used to treat MERS, another coronavirus variant.

It isn't a cure for the virus because the body's own immune system is the only way to fight a virus, but the treatment does help prevent the inflammation which actually kills most patients.


No comments:

Post a Comment